The combination treatment of anti-VEGF and anti-PD-L1 activates intratumoral DCs and T cells and reaches maximal efficacy when combined with agonistic LTRβ antibodies; this triple treatment induces HEV+ immune clusters even in highly therapy-resistant GBM (115). The gene discussed is VEGFA; the disease is glioblastoma.